LEADS BIOLABS-B (09887) announced that the first patient has been successfully enrolled in a Phase II clinical study evaluating VELISIN™ (PD-L1/4-1BB bispecific antibody, Opatisumimab, LBL-024) for the treatment of first-line esophageal squamous cell carcinoma. This open-label, multicenter Phase II clinical study is led by Professor Lin Shen, Director of Peking University Cancer Hospital, and is being conducted simultaneously at multiple hospitals across the country. The trial aims to evaluate the efficacy and safety of Opatisumimab in treating patients with first-line esophageal squamous cell carcinoma.